CLINICAL RELEVANCE: DRUG–DRUG INTERACTION,PHARMACOKINETICS,PHARMACODYNAMICS, AND TOXICITY - Drug Transporters: Molecular Characterization and Role in Drug Disposition - page 823

115. Gramatte T, Oertel R. 1999. Intestinal secretion of intravenous talinolol is inhibited by
luminal R-verapamil. Clin Pharmacol Ther 66: 239-245.
116. Schwarz UI, Gramatte T, Krappweis J, Berndt A, Oertel R, von Richter O, Kirch W.
1999. Unexpected effect of verapamil on oral bioavailability of the -blocker talinolol in
humans. Clin Pharmacol Ther 65: 283-290.
117. Gramatte T, Oertel R, Terhaag B, Kirch W. 1996. Direct demonstration of small intesti-
nal secretion and site-dependent absorption of the -blocker talinolol in humans. Clin

Pharmaocol Ther 59: 541-549.
118. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer
HK. 1999. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin.
J Clin Invest 104: 147-153.
119. Westphal K, Weinbrenner A, Zschiesche M, Franke G, Knoke M, Oertel R, Fritz P, von
Richter O, Warzok R, Hachenberg T, et al. 2000. Induction of P-glycoprotein by rifampin
increases intestinal secretion of talinolol in human beings: a new type of drug/drug inter-
action. Clin Pharmacol Ther 68: 345-355.
120. Hamman MA, Bruce MA, Haehner-Daniels BD, Hall SD. 2001. The effect of rifampin
administration on the disposition of fexofenadine. Clin Pharmacol Ther 69: 114-121.
121. Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ. 1992. Bioavailability of cyclosporine
with concomitant rifampin administration is markedly less than predicted by hepatic
enzyme induction. Clin Pharmacol Ther 52: 453-457.
122. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB 1999. OATP and P-
glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug
Metab Dispos 27: 866-871.
123. Ruschitzka F, Mejer PJ, Turina M, Luscher TF, Noll G. 2000. Acute heart transplant
rejection due to Saint John's wort. Lancet 355: 548-549.
124. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. 2000. Indinavir concentrations
and St John's wort. Lancet 355: 547-548.
125. Durr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K.
2000. St. John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic
CYP3A4. Clin Pharmacol Ther 68: 598-604.
126. Zhou S, Chan E, Pan SQ, Huang M, Lee EJ. 2004. Pharmacokinetic interactions of drugs
with St. John's wort. J Psychopharmacol 18: 262-276.
127. Schwarz UI, Buschel B, Kirch W. 2003. Unwanted pregnancy on self-medication
with St. John's wort despite hormonal contraception. Br J Clin Pharmacol 55: 112-
113.
128. Dresser GK, Schwarz UI, Wilkinson GR, Kim RB. 2003. Coordinate induction of both
cytochrome P4503A and MDR1 by St. John's wort in healthy subjects. Clin Pharmacol
Ther 73: 41-50.
129. Wang Z, Hamman MA, Huang SM, Lesko LJ, Hall SD. 2002. Effect of St. John's wort
on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 71: 414-420.
130. Mai I, Stormer E, Bauer S, Kruger H, Budde K, Roots I. 2003. Impact of St. John's
wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal
transplant patients. Nephrol Dial Transplant 18: 819-822.
131. Hebert MF, Park JM, Chen YL, Akhtar S, Larson AM. 2004. Effects of St. John's wort
( Hypericum perforatum ) on tacrolimus pharmacokinetics in healthy volunteers. J Clin
Pharmacol 44: 89-94.